文献速递免疫规划卫生政策与健康促进

英国人乳头瘤病毒疫苗接种的成本效果:九价HPV疫苗两剂次与单剂次比较

Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination.
PubMed 文献 · Am J Prev Med · 2024-03-18

该研究采用年龄结构动态模型,从医疗保健视角评估英国2023至2093年对12至13岁人群接种九价HPV疫苗单剂次与两剂次的长期健康和经济结局。结果显示,与假设10年内90%有效的单剂次方案相比,两剂次方案不具有成本效果,其增量成本效果比为每质量调整生命年230,903至1,082,916英镑,远超英国20,000英镑/质量调整生命年的支付意愿阈值。

要点

  • 两剂次方案相比单剂次方案的增量成本效果比为每QALY 230,903至1,082,916英镑,超过英国20,000英镑/QALY阈值。
  • 单剂次方案相比不接种具有成本效果,增量成本效果比低于2,040英镑/QALY。

核心结论

  • 研究证实英国单剂次HPV疫苗具有成本效果,与2023年9月的政策转变一致。
  • 该转变不仅带来财务收益,还简化了疫苗接种实施,策略性地减少了HPV的流行病学和经济影响。

研究设计与样本

  • 采用年龄结构动态模型,从医疗保健视角分析单剂次与两剂次九价HPV疫苗接种策略的长期健康和经济结局。
  • 研究对象为2023至2093年间接种九价HPV疫苗的12至13岁人群。
  • 分析于2023至2024年进行,探索了单剂次策略下不同免疫持续时间(10年、30年或终身)和效力水平。

主要发现

  • 在英国,与假设10年内90%有效的单剂次方案相比,12至13岁人群两剂次方案不具有成本效果。
  • 两剂次方案的增量成本效果比为每质量调整生命年230,903至1,082,916英镑,显著超过英国20,000英镑/质量调整生命年的支付意愿阈值。
  • 单剂次方案相比不接种具有成本效果,增量成本效果比低于每质量调整生命年2,040英镑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The UK implemented a single-dose HPV vaccination policy in September 2023, aiming for sustained protection, better vaccine coverage, and reduced healthcare costs. This research assesses the cost-effectiveness of both one-dose and two-dose schedules from a healthcare perspective. METHODS: Using an age-structured dynamic model, the study analyzed long-term health and economic outcomes of these two different vaccination approaches. It focused on the effects of vaccinating 12- to 13-year-olds with the 9-valent HPV vaccine in either single-dose or two-dose regimens from 2023 to 2093. The analysis, conducted in 2023-2024, explored different immunity durations (10, 30 years, or lifetime) and efficacy levels for the single-dose strategy. RESULTS: The study indicated that in the UK, vaccinating 12- to 13-year-olds with a two-dose regimen is not considered cost-effective compared to the single-dose option, assumed to be 90% as effective for 10 years. The incremental cost-effectiveness ratios for two doses ranged from £230,903 to £1,082,916 per quality-adjusted life year (QALY), significantly exceeding the UK's £20,000/QALY willingness-to-pay threshold. Over 70 years, a switch from a two-dose to a single-dose vaccination schedule could potentially lead to savings of over £1,073 million in the healthcare system. Furthermore, the single-dose regimen was cost-effective compared to no vaccination, with an incremental cost-effectiveness ratio below £2,040/QALY. CONCLUSIONS: The study affirms the cost-effectiveness of the UK's single-dose HPV vaccine, in sync with its September 2023 policy shift. The shift not only provides financial benefits but also simplifies vaccine administration, strategically reducing HPV's epidemiological and economic impacts.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Song Y, Choi W, Shim E, et al. Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination. Am J Prev Med. 2024. PMID: 38508425. doi:10.1016/j.amepre.2024.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。